Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia

Despite the proven efficacy of SGLT-2 inhibitors and GLP-1 agonists, their adoption in cardiology is limited by familiarity gaps, cost concerns, and safety issues. Enhanced education, better access to guidelines, and addressing cost barriers are crucial steps to improve the adoption of these medications in clinical practice.